Copyright Reports & Markets. All rights reserved.

Global Furmonertinib Mesylate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Furmonertinib Mesylate Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 40 mg
    • 1.3.3 80 mg
  • 1.4 Market Analysis by Sales Channels
    • 1.4.1 Overview: Global Furmonertinib Mesylate Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Retail
    • 1.4.4 Online
  • 1.5 Market Analysis by Application
    • 1.5.1 Overview: Global Furmonertinib Mesylate Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.5.2 Non-small Cell Lung Cancer (NSCLC) Treatment
    • 1.5.3 Patients With Central Nervous System Metastases
    • 1.5.4 First-line and Later-line Targeted Therapy
    • 1.5.5 Others
  • 1.6 Global Furmonertinib Mesylate Market Size & Forecast
    • 1.6.1 Global Furmonertinib Mesylate Consumption Value (2021 & 2025 & 2032)
    • 1.6.2 Global Furmonertinib Mesylate Sales Quantity (2021-2032)
    • 1.6.3 Global Furmonertinib Mesylate Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Allist Pharmaceuticals
    • 2.1.1 Allist Pharmaceuticals Details
    • 2.1.2 Allist Pharmaceuticals Major Business
    • 2.1.3 Allist Pharmaceuticals Furmonertinib Mesylate Product and Services
    • 2.1.4 Allist Pharmaceuticals Furmonertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Allist Pharmaceuticals Recent Developments/Updates
  • 2.2 Jiangsu Allist Biopharmaceutical
    • 2.2.1 Jiangsu Allist Biopharmaceutical Details
    • 2.2.2 Jiangsu Allist Biopharmaceutical Major Business
    • 2.2.3 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product and Services
    • 2.2.4 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Jiangsu Allist Biopharmaceutical Recent Developments/Updates
  • 2.3 TargetMol
    • 2.3.1 TargetMol Details
    • 2.3.2 TargetMol Major Business
    • 2.3.3 TargetMol Furmonertinib Mesylate Product and Services
    • 2.3.4 TargetMol Furmonertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 TargetMol Recent Developments/Updates
  • 2.4 MedChemExpress
    • 2.4.1 MedChemExpress Details
    • 2.4.2 MedChemExpress Major Business
    • 2.4.3 MedChemExpress Furmonertinib Mesylate Product and Services
    • 2.4.4 MedChemExpress Furmonertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 MedChemExpress Recent Developments/Updates

3 Competitive Environment: Furmonertinib Mesylate by Manufacturer

  • 3.1 Global Furmonertinib Mesylate Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Furmonertinib Mesylate Revenue by Manufacturer (2021-2026)
  • 3.3 Global Furmonertinib Mesylate Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Furmonertinib Mesylate by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Furmonertinib Mesylate Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Furmonertinib Mesylate Manufacturer Market Share in 2025
  • 3.5 Furmonertinib Mesylate Market: Overall Company Footprint Analysis
    • 3.5.1 Furmonertinib Mesylate Market: Region Footprint
    • 3.5.2 Furmonertinib Mesylate Market: Company Product Type Footprint
    • 3.5.3 Furmonertinib Mesylate Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Furmonertinib Mesylate Market Size by Region
    • 4.1.1 Global Furmonertinib Mesylate Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Furmonertinib Mesylate Consumption Value by Region (2021-2032)
    • 4.1.3 Global Furmonertinib Mesylate Average Price by Region (2021-2032)
  • 4.2 North America Furmonertinib Mesylate Consumption Value (2021-2032)
  • 4.3 Europe Furmonertinib Mesylate Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Furmonertinib Mesylate Consumption Value (2021-2032)
  • 4.5 South America Furmonertinib Mesylate Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Furmonertinib Mesylate Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
  • 5.2 Global Furmonertinib Mesylate Consumption Value by Type (2021-2032)
  • 5.3 Global Furmonertinib Mesylate Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
  • 6.2 Global Furmonertinib Mesylate Consumption Value by Application (2021-2032)
  • 6.3 Global Furmonertinib Mesylate Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
  • 7.2 North America Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
  • 7.3 North America Furmonertinib Mesylate Market Size by Country
    • 7.3.1 North America Furmonertinib Mesylate Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Furmonertinib Mesylate Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
  • 8.2 Europe Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
  • 8.3 Europe Furmonertinib Mesylate Market Size by Country
    • 8.3.1 Europe Furmonertinib Mesylate Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Furmonertinib Mesylate Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Furmonertinib Mesylate Market Size by Region
    • 9.3.1 Asia-Pacific Furmonertinib Mesylate Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Furmonertinib Mesylate Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
  • 10.2 South America Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
  • 10.3 South America Furmonertinib Mesylate Market Size by Country
    • 10.3.1 South America Furmonertinib Mesylate Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Furmonertinib Mesylate Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Furmonertinib Mesylate Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Furmonertinib Mesylate Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Furmonertinib Mesylate Market Size by Country
    • 11.3.1 Middle East & Africa Furmonertinib Mesylate Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Furmonertinib Mesylate Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Furmonertinib Mesylate Market Drivers
  • 12.2 Furmonertinib Mesylate Market Restraints
  • 12.3 Furmonertinib Mesylate Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Furmonertinib Mesylate and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Furmonertinib Mesylate
  • 13.3 Furmonertinib Mesylate Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Furmonertinib Mesylate Typical Distributors
  • 14.3 Furmonertinib Mesylate Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Furmonertinib Mesylate market size was valued at US$ 971 million in 2025 and is forecast to a readjusted size of US$ 1934 million by 2032 with a CAGR of 11.6% during review period.
    In 2025, global Furmonertinib Mesylate Tablets production reached approximately 380,000 units.Furmonertinib Mesylate is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily used for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations or the T790M resistance mutation. It works by selectively and irreversibly inhibiting the kinase activity of mutant EGFR, thereby blocking tumor cell proliferation and survival signaling pathways and suppressing tumor growth. Furmonertinib mesylate is characterized by high selectivity for mutant EGFR, good central nervous system penetration, and a relatively manageable safety profile, making it clinically valuable in the treatment of advanced non-small cell lung cancer.
    Furmonertinib Mesylate, as a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), operates in a rapidly developing and highly competitive segment of the non-small cell lung cancer (NSCLC) targeted therapy market, particularly demonstrating strong competitiveness in patients with EGFR mutations and T790M resistance mutations. With the large population of lung cancer patients and the continuous improvement in the penetration of genetic testing, the demand for precision medicine is steadily increasing, providing a solid market foundation for this class of drugs.
    From a competitive landscape perspective, imported originator drugs represented by Osimertinib have long dominated the market. However, furmonertinib mesylate, leveraging its domestic R&D advantages, price competitiveness, and potential efficacy in patients with central nervous system metastases, is gradually gaining market share in China.
    On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, multiple third-generation EGFR-TKIs and next-generation targeted therapies from both domestic and international companies are continuously entering the market. In addition, the development of immunotherapy combination regimens is further intensifying competition. Therefore, the future market performance of furmonertinib mesylate will depend on its penetration in first-line treatment, expansion of indications (such as adjuvant therapy or additional mutation subtypes), and the accumulation of real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and pricing.
    This report is a detailed and comprehensive analysis for global Furmonertinib Mesylate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Furmonertinib Mesylate market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Furmonertinib Mesylate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Furmonertinib Mesylate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Furmonertinib Mesylate market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Furmonertinib Mesylate
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Furmonertinib Mesylate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Allist Pharmaceuticals, Jiangsu Allist Biopharmaceutical, TargetMol, MedChemExpress, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Furmonertinib Mesylate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    40 mg
    80 mg
    Market segment by Sales Channels
    Hospital
    Retail
    Online
    Market segment by Application
    Non-small Cell Lung Cancer (NSCLC) Treatment
    Patients With Central Nervous System Metastases
    First-line and Later-line Targeted Therapy
    Others
    Major players covered
    Allist Pharmaceuticals
    Jiangsu Allist Biopharmaceutical
    TargetMol
    MedChemExpress
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Furmonertinib Mesylate product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Furmonertinib Mesylate, with price, sales quantity, revenue, and global market share of Furmonertinib Mesylate from 2021 to 2026.
    Chapter 3, the Furmonertinib Mesylate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Furmonertinib Mesylate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Furmonertinib Mesylate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Furmonertinib Mesylate.
    Chapter 14 and 15, to describe Furmonertinib Mesylate sales channel, distributors, customers, research findings and conclusion.

    Buy now